CN115873904A - 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞 - Google Patents

使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞 Download PDF

Info

Publication number
CN115873904A
CN115873904A CN202211654230.0A CN202211654230A CN115873904A CN 115873904 A CN115873904 A CN 115873904A CN 202211654230 A CN202211654230 A CN 202211654230A CN 115873904 A CN115873904 A CN 115873904A
Authority
CN
China
Prior art keywords
nucleic acid
polypeptide
fragment
vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211654230.0A
Other languages
English (en)
Chinese (zh)
Inventor
R.R.克彻姆
J.T.麦格鲁
D.A.富米纳亚林
T.P.蒙罗
N.J.阿格拉沃尔
K.M.达里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN115873904A publication Critical patent/CN115873904A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
    • C12Y104/01002—Glutamate dehydrogenase (1.4.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04004—Adenylosuccinate synthase (6.3.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202211654230.0A 2016-05-11 2017-05-11 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞 Pending CN115873904A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662334966P 2016-05-11 2016-05-11
US62/334966 2016-05-11
CN201780034550.7A CN109219660B (zh) 2016-05-11 2017-05-11 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞
PCT/US2017/032139 WO2017197098A1 (en) 2016-05-11 2017-05-11 Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780034550.7A Division CN109219660B (zh) 2016-05-11 2017-05-11 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞

Publications (1)

Publication Number Publication Date
CN115873904A true CN115873904A (zh) 2023-03-31

Family

ID=58873869

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211654230.0A Pending CN115873904A (zh) 2016-05-11 2017-05-11 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞
CN201780034550.7A Expired - Fee Related CN109219660B (zh) 2016-05-11 2017-05-11 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780034550.7A Expired - Fee Related CN109219660B (zh) 2016-05-11 2017-05-11 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞

Country Status (17)

Country Link
US (2) US11384140B2 (https=)
EP (2) EP4067493A1 (https=)
JP (2) JP6972022B2 (https=)
KR (2) KR102439719B1 (https=)
CN (2) CN115873904A (https=)
AU (2) AU2017263454B2 (https=)
BR (1) BR112018073316A2 (https=)
CA (1) CA3024027A1 (https=)
CL (1) CL2018003210A1 (https=)
EA (1) EA201892588A1 (https=)
ES (1) ES2914118T3 (https=)
IL (2) IL300591A (https=)
MA (1) MA44976A (https=)
MX (2) MX394682B (https=)
SG (1) SG11201810040WA (https=)
TW (2) TWI821905B (https=)
WO (1) WO2017197098A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12173340B2 (en) * 2016-11-16 2024-12-24 Agency For Science, Technology And Research Attenuated glutamine synthetase as a selection marker
IL270817B2 (en) 2017-05-24 2025-10-01 Thoeris Gmbh Use of glutamine synthetase to treat hyperammonemia
CN109988777A (zh) * 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
US12559760B2 (en) * 2019-05-07 2026-02-24 Amgen Inc. Vectors and expression systems for producing recombinant proteins
EP4384623A4 (en) * 2021-08-03 2025-09-24 Shanghai Zhenge Biotechnology Co Ltd SELECTABLE MARKERS FOR EUKARYOTIC EXPRESSION SYSTEM
WO2023125389A1 (en) * 2021-12-27 2023-07-06 Shanghai Zhenge Biotechnology Co., Ltd. Novel markers for recombinant production system
AU2023238775A1 (en) 2022-03-23 2024-10-31 Boehringer Ingelheim International Gmbh Bacterial glutamine synthetase as selection marker in mammalian cells
CA3252382A1 (en) * 2022-03-23 2023-09-28 Boehringer Ingelheim International Gmbh NEW VARIANTS OF GLUTAMINE SYNTHETASE AS A SELECTION MARKER
WO2025037708A1 (en) * 2023-08-16 2025-02-20 Korea Advanced Institute Of Science And Technology Method for selection of cell line expressing high levels of recombinant protein using glutamine synthetase split expression vector
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
CN118006685B (zh) * 2024-04-07 2024-07-23 上海碧博生物医药科技有限公司 一种快速的高表达单克隆细胞株构建方法
KR20250169382A (ko) * 2024-05-23 2025-12-03 한국과학기술원 디히드로엽산 환원효소 분할 발현벡터를 이용한 재조합 단백질 고발현 세포주의 선별방법
WO2025250814A1 (en) * 2024-05-31 2025-12-04 Amgen Inc. Intein based split glutamine synthetase engineering

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035887A1 (en) * 2001-09-20 2003-05-01 Immunex Corporation Selection of cells expressing heteromeric polypeptides
WO2004038003A2 (en) * 2002-10-25 2004-05-06 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20040148647A1 (en) * 2002-11-29 2004-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
CN1966682A (zh) * 2002-01-17 2007-05-23 英国龙沙生物医药股份有限公司 能够产生蛋白质及能够在无谷氨酰胺的培养基上生长的谷氨酰胺营养缺陷型人类细胞
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants
WO2012095514A1 (en) * 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
US20120196321A1 (en) * 2010-08-25 2012-08-02 Genomatica, Inc. Selectable markers and related methods
US20120301919A1 (en) * 2011-05-24 2012-11-29 Agency For Science, Technology And Research Ires mediated multicistronic vectors
US20130244231A1 (en) * 2010-11-08 2013-09-19 Jcr Pharmaceuticals Co., Ltd. Novel expression vector

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH0819508B2 (ja) 1987-08-19 1996-02-28 三菱マテリアル株式会社 Ｆｅ−Ｃｏ基合金製高周波用磁芯材
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5624818A (en) 1991-09-09 1997-04-29 Fred Hutchinson Cancer Research Center Nucleic acids encoding regulatory proteins that dimerize with Mad or Max
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5573925A (en) 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
MX9709447A (es) 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DK1196566T3 (da) 1999-07-12 2006-06-06 Genentech Inc Ekspressionsvektorer og -metoder
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
ATE532861T1 (de) 2003-09-04 2011-11-15 Medarex Inc Expressionsvektor
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
KR101411740B1 (ko) * 2012-05-29 2014-06-27 한화케미칼 주식회사 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035887A1 (en) * 2001-09-20 2003-05-01 Immunex Corporation Selection of cells expressing heteromeric polypeptides
US20030082735A1 (en) * 2001-09-20 2003-05-01 McGrew Jeffrey T. Selection of cells expressing heteromeric polypeptides
EP1434871A1 (en) * 2001-09-20 2004-07-07 Immunex Corporation Selection of cells expressing heteromeric polypeptides
CN1966682A (zh) * 2002-01-17 2007-05-23 英国龙沙生物医药股份有限公司 能够产生蛋白质及能够在无谷氨酰胺的培养基上生长的谷氨酰胺营养缺陷型人类细胞
WO2004038003A2 (en) * 2002-10-25 2004-05-06 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20040148647A1 (en) * 2002-11-29 2004-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants
US20120196321A1 (en) * 2010-08-25 2012-08-02 Genomatica, Inc. Selectable markers and related methods
US20130244231A1 (en) * 2010-11-08 2013-09-19 Jcr Pharmaceuticals Co., Ltd. Novel expression vector
WO2012095514A1 (en) * 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
US20120301919A1 (en) * 2011-05-24 2012-11-29 Agency For Science, Technology And Research Ires mediated multicistronic vectors

Also Published As

Publication number Publication date
IL300591A (en) 2023-04-01
EA201892588A1 (ru) 2019-06-28
CL2018003210A1 (es) 2019-02-15
TWI757291B (zh) 2022-03-11
TW202223093A (zh) 2022-06-16
JP2022033734A (ja) 2022-03-02
WO2017197098A1 (en) 2017-11-16
US20190127452A1 (en) 2019-05-02
US12516111B2 (en) 2026-01-06
IL262923B2 (en) 2023-08-01
MX2018013882A (es) 2019-03-14
MX394682B (es) 2025-03-24
US20230048658A1 (en) 2023-02-16
JP2019514417A (ja) 2019-06-06
AU2017263454B2 (en) 2023-02-09
MA44976A (fr) 2019-03-20
AU2017263454A1 (en) 2018-12-06
EP3455359A1 (en) 2019-03-20
BR112018073316A2 (pt) 2019-06-04
IL262923B1 (en) 2023-04-01
KR20190005193A (ko) 2019-01-15
TWI821905B (zh) 2023-11-11
IL262923A (en) 2019-01-31
AU2023200660B2 (en) 2024-12-12
KR102439719B1 (ko) 2022-09-02
CN109219660B (zh) 2023-01-06
JP7344949B2 (ja) 2023-09-14
MX2022009674A (es) 2022-09-09
CN109219660A (zh) 2019-01-15
AU2023200660A1 (en) 2023-03-09
EP3455359B1 (en) 2022-03-09
TW201805422A (zh) 2018-02-16
SG11201810040WA (en) 2018-12-28
JP6972022B2 (ja) 2021-11-24
ES2914118T3 (es) 2022-06-07
EP4067493A1 (en) 2022-10-05
CA3024027A1 (en) 2017-11-16
KR102323519B1 (ko) 2021-11-09
KR20210135635A (ko) 2021-11-15
US11384140B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
US12516111B2 (en) Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
JP7788307B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
JP2011518790A (ja) ポリクローナルタンパク質を製造する方法
EP3467117B1 (en) Selection of cells expressing heteromeric polypeptides
HK40082650A (en) Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
US20220243222A1 (en) Vectors and expression systems for producing recombinant proteins
EA043386B1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
TW202328442A (zh) 平臺宿主對ｉｇｆ—培養基之適應
EA047078B1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230331

WD01 Invention patent application deemed withdrawn after publication